A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Clinical trial NCT05104866 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05104866
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-18
- Primary completion
- 2024-07-24
- Enrollment
- 732
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.